Krebs Biochemicals & Industries Ltd
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Closing Inventory - Finished Goods (Total) ₹ Lakhs ・Standalone data |
|
||||||||||
| Revenue from Sale of Services (Contract Manufacturing/Job Work) ₹ Lakhs ・Standalone data |
|||||||||||
| Total Regular Employees Number ・Standalone data |
|||||||||||
| Installed Capacity - Simvastatin (Anti-cholesterol) MT per month ・Standalone data |
|||||||||||
Documents
Announcements
-
Closure of Trading Window
19 Mar - Trading window closed from COB March 31, 2026 until 48 hours after audited FY2026 results; board date to be notified.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 Feb - Company has enclosing copy of newspaper advertisement of financial results for the quarter ended 31.12.2025
-
Results Quarter Ended 31.12.2025
9 Feb - Q3/9M Dec 31,2025 results: Q3 revenue Rs727.42l, 9M loss Rs1,459.35l; Vizag plant closed 07 Feb 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting
9 Feb - Q3/9M FY26 unaudited results: Q3 loss Rs.312.65L, 9M loss Rs.1,459.35L; limited review unmodified.
-
Board Meeting Intimation for Board Meeting Intimation To Consider And Adopt The Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended December 31, 2025
14 Jan - Board meeting Feb 9, 2026 to adopt Q3/9M Dec 31, 2025 results; trading window closed until 48 hours after declaration.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Portfolio
a) Androstenedione which is used as Steroid Intermediate
b) Lovastatin used as Anti-cholesterol medication
c) Simvastatin is also used as Anti-cholesterol medication
d) Upcoming Products: Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase and Phenylephrine. [1]